In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
Hims & Hers Health Inc (NYSE: HIMS) closed the day trading at $54.02 down -1.30% from the previous closing price of $54.73. In other words, the price has decreased by -$1.30 from its previous closing price. On the day, 21.05 million shares were traded. HIMS stock price reached its highest trading level at $55.14 during the session, while it also had its lowest trading level at $51.75.
Ratios:
For a better understanding of HIMS, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.67 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 104.83. For the most recent quarter (mrq), Quick Ratio is recorded 4.46 and its Current Ratio is at 4.98. In the meantime, Its Debt-to-Equity ratio is 1.86 whereas as Long-Term Debt/Eq ratio is at 1.85.
On June 04, 2025, Needham reiterated its Buy rating and also lowered its target price recommendation from $61 to $65.
TD Cowen Downgraded its Buy to Hold on April 29, 2025, while the target price for the stock was maintained at $30.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 10 ’25 when Chi Michael sold 900 shares for $58.25 per share. The transaction valued at 52,425 led to the insider holds 291,439 shares of the business.
Boughton Soleil sold 2,637 shares of HIMS for $143,400 on Oct 13 ’25. The Chief Legal Officer now owns 161,130 shares after completing the transaction at $54.38 per share. On Oct 13 ’25, another insider, Boughton Soleil, who serves as the Officer of the company, bought 2,637 shares for $54.38 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HIMS now has a Market Capitalization of 12209577984 and an Enterprise Value of 12109350912. As of this moment, Hims’s Price-to-Earnings (P/E) ratio for their current fiscal year is 67.61, and their Forward P/E ratio for the next fiscal year is 68.48. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.65. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.06 while its Price-to-Book (P/B) ratio in mrq is 21.67. Its current Enterprise Value per Revenue stands at 6.014 whereas that against EBITDA is 75.611.
Stock Price History:
The Beta on a monthly basis for HIMS is 2.23, which has changed by 1.4159212 over the last 52 weeks, in comparison to a change of 0.13724327 over the same period for the S&P500. Over the past 52 weeks, HIMS has reached a high of $72.98, while it has fallen to a 52-week low of $18.33. The 50-Day Moving Average of the stock is 6.09%, while the 200-Day Moving Average is calculated to be 20.40%.
Shares Statistics:
Over the past 3-months, HIMS traded about 30.11M shares per day on average, while over the past 10 days, HIMS traded about 27521490 shares per day. A total of 217.38M shares are outstanding, with a floating share count of 202.68M. Insiders hold about 10.33% of the company’s shares, while institutions hold 77.82% stake in the company. Shares short for HIMS as of 1759190400 were 71013939 with a Short Ratio of 2.36, compared to 1756425600 on 74635929. Therefore, it implies a Short% of Shares Outstanding of 71013939 and a Short% of Float of 38.93.
Earnings Estimates
. The current assessment of Hims & Hers Health Inc (HIMS) involves the perspectives of 12.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $0.13, with high estimates of $0.2 and low estimates of $0.04.
Analysts are recommending an EPS of between $0.72 and $0.42 for the fiscal current year, implying an average EPS of $0.59. EPS for the following year is $0.81, with 12.0 analysts recommending between $1.43 and $0.4.
Revenue Estimates
12 analysts predict $578.99M in revenue for . The current quarter. It ranges from a high estimate of $590.87M to a low estimate of $567.56M. As of . The current estimate, Hims & Hers Health Inc’s year-ago sales were $401.56MFor the next quarter, 12 analysts are estimating revenue of $627.06M. There is a high estimate of $685.04M for the next quarter, whereas the lowest estimate is $589.5M.
A total of 14 analysts have provided revenue estimates for HIMS’s current fiscal year. The highest revenue estimate was $2.41B, while the lowest revenue estimate was $2.3B, resulting in an average revenue estimate of $2.34B. In the same quarter a year ago, actual revenue was $1.48BBased on 13 analysts’ estimates, the company’s revenue will be $2.79B in the next fiscal year. The high estimate is $3B and the low estimate is $2.5B.
